600867.SS SHH
Tonghua Dongbao Pharmaceutical Co., Ltd.
1W: -0.1%
1M: -3.1%
3M: -5.2%
YTD: -11.4%
1Y: -6.8%
3Y: -17.2%
5Y: -24.9%
¥7.86 ($1.17)
+0.18 (+2.34%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$2.0B
-34.7% ▼
5Y CAGR: -6.3%
Gross Profit
$1.5B
-40.4% ▼
5Y CAGR: -6.5%
Operating Income
$168M
-87.7% ▼
5Y CAGR: -29.5%
Net Income
-$43M
-103.7% ▼
EPS (Diluted)
$-0.02
-103.4% ▼
EBITDA
$300M
-79.4% ▼
5Y CAGR: -22.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.3B | $2.8B | $3.1B | $2.0B |
| YoY Growth | +4.1% | +13.0% | -15.0% | +10.7% | -34.7% |
| Cost of Revenue | $583M | $587M | $628M | $621M | $547M |
| Gross Profit | $2.3B | $2.7B | $2.2B | $2.5B | $1.5B |
| Gross Margin | 79.8% | 82.0% | 77.4% | 79.8% | 72.8% |
| R&D Expenses | $107M | $167M | $147M | $75M | $102M |
| SG&A Expenses | $1.1B | $1.3B | $1.1B | $1.0B | $1.3B |
| Operating Expenses | $1.1B | $1.1B | $321M | $1.1B | $1.3B |
| Operating Income | $1.2B | $1.5B | $1.8B | $1.4B | $168M |
| Operating Margin | 40.8% | 47.4% | 65.8% | 44.4% | 8.4% |
| Interest Expense | $10M | $226K | $489K | $7M | $15M |
| Income Before Tax | $1.1B | $1.5B | $1.8B | $1.4B | -$144M |
| Tax Expense | $178M | $226M | $248M | $198M | -$100M |
| Net Income | $930M | $1.3B | $1.6B | $1.2B | -$43M |
| Net Margin | 32.2% | 40.0% | 56.9% | 38.0% | -2.1% |
| EPS (Diluted) | $0.46 | $0.64 | $0.80 | $0.59 | $-0.02 |
| EBITDA | $1.3B | $1.4B | $1.0B | $1.5B | $300M |
| Shares Outstanding | 2.02B | 2.04B | 1.97B | 1.98B | 2.14B |